Citations

Clear

38 citation(s) found for "Kim, Se Eun".

WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids
Jung, Dawa, Kendi, A. Tuba , Woodrum, David A. , In, Myung‐Ho , Bilgin, Gokce Belge , Johnson, Derek R. , Kim, Eun-Joo, Chung, Jin Ook , Park, Seon-Young , Curran, Geoffry L., Lowe, Val J. , Lee, Seung Baek , Kendi, A Tuba , Adamo, Daniel A. , In, Myung-Ho , Belge Bilgin, Gokce , Johnson, Derek R , Horn, Ian M, Lowe, Val J , Lee, Seung Baek , Thompson, Scott M. , Horn, Ian M. , Curran, Geoffry L.

Mayo Clinic

International Journal of Molecular Sciences | August 3, 2026 | Volume: 27 | Issue: 15 | Pages: 6899

10.3390/ijms27156899 | PMID 42589556 Get It

Long-established prostate cancer cell lines provide limited insight into how contemporary early prostate cancer evolves into drug-resistant and neuroendocrine-like refractory disease. Patient-derived three-dimensional (3D) ex vivo models may better preserve this transition. Here, we found that 8 of 10 magnetic resonance imaging-guided biopsy specimens from patients with early-stage prostate cancer generated sustained 3D tumor spheroid cultures. After 12 weeks of enzalutamide selection, only one patient-derived culture acquired a resistant phenotype with treatment-emergent neuroendocrine prostate cancer (t-NEPC)-like features, including increased chromogranin A (CgA) and synaptophysin (SYP); reduced androgen receptor (AR), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA); and conversion from compact spheroids into irregular resistant aggregates. During this transition, WD repeat and SOCS box-containing protein 1 (WSB1) increased, whereas PSMA progressively decreased. WSB1 silencing restored PSMA, AR, and PSA expression and reduced neuroendocrine-associated features. A similar WSB1 dependency was observed in enzalutamide-resistant LNCaP cells, the castration-resistant prostate cancer model 22Rv1, and the neuroendocrine/small-cell prostate cancer model NCI-H660. Mechanistically, WSB1 functioned as a SOCS box-dependent E3 ubiquitin ligase adaptor that promoted PSMA ubiquitination and degradation. SOCS box deletion or T380A mutation impaired this process, while Aurora kinase A (AURKA) inhibition reduced WSB1-dependent PSMA ubiquitination. WSB1 depletion, AURKA inhibition with alisertib, and combined AURKA inhibition with EZH2 suppression reduced resistant aggregate growth and increased apoptosis-associated markers in patient-derived enzalutamide-resistant neuroendocrine-like spheroids and related models. These findings nominate the AURKA–WSB1–PSMA axis as a therapeutic vulnerability in refractory prostate cancer.
Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies
Morganti, Stefania , Kim, Se Eun , Jin, Qingchun , Cha, Jaeyoon , Zeigler, Jacqueline E, Newman, Alexandra Bili, Kirkner, Gregory J. , Snow, Craig , Zheng, Yue, Vincuilla, Julie, Parker, Tonia , Buehler, Ryan M. , Bychkovsky, Brittany L , Dibble, Kate E. , Sella, Tal , Ruddy, Kathryn J, Rosenberg, Shoshana M, Collins, Laura C. , Peppercorn, Jeffrey, Schapira, Lidia, Guzman-Arocho, Yaileen D, Come, Steven E. , Warner, Ellen, Poorvu, Philip D. , Lambertini, Matteo, Curigliano, G, Hughes, Melissa E. , Mittendorf, Elizabeth A, King, Tari A, Lin, Nancy U, Garber, Judy E, Tayob, Nabihah, Tolaney, S M, Partridge, Ann H, Zheng, Yue , Newman, Alexandra B , Zheng, Yue , Ruddy, Kathryn J , Peppercorn, Jeffrey M , Borges, Virginia F , Guzman-Arocho, Yaileen D , Come, Steven , Poorvu, Philip D , Lambertini, Matteo , Curigliano, Giuseppe , Mittendorf, EA , King, Tari A , Lin, Nancy U , Garber, J. E. , Tayob, Nabihah , Tolaney, Sara , Partridge, Ann H , Lynce, Filipa , Kirkner, Gregory , Snow, Craig , Vincuilla, Julie, Ruddy, Kathryn J. , Rosenberg, Shoshana M. , Peppercorn, Jeffrey , Schapira, Lidia , Borges, Virginia F. , Guzmán‐Arocho, Yaileen D. , Warner, Ellen , Lambertini, Matteo , Curigliano, Giuseppe , King, Tari A. , Lin, Nancy U. , Garber, Judy E. , Partridge, Ann H.

Mayo Clinic

JNCI Cancer Spectrum | May 23, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1093/jncics/pkag055 | PMID 42185079 Get It

Abstract Background Whether outcomes of germline BRCA1/2 (gBRCA1/2)-associated breast cancer differ compared with sporadic tumors is controversial. We explored the impact of gBRCA1/2 pathogenic variant (PV) status beyond established prognostic features. Methods We conducted 2 retrospective, matched cohort studies comparing gBRCA1/2 PV carriers and noncarriers with HER2-negative, stage I-III breast cancer (Clinical Outcomes Quality Database [COQD] cohort: 185 carriers, 555 noncarriers; Young Women’s Breast Cancer Study [YWS] cohort: 113 carriers, 226 noncarriers). Matching factors were age, stage, hormone receptor status, and year of diagnosis. Clinicopathological features, treatments, and survival outcomes were compared between carriers and noncarriers. Results Most patients in COQD had stage I-II disease (87.2%), and more carriers than noncarriers had genetic testing before diagnosis (33% vs 5.6%, P < .001). In YWS, 22.7% of patients had stage III tumors, and few were tested before diagnosis (14.8% of carriers vs 1.7% of noncarriers; P < .001). Carriers in COQD received chemotherapy more often than noncarriers (81.1 vs 67.0%, P < .001), including platinum (P = .010); the proportion was similar for carriers and noncarriers in YWS. After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts. Triple-negative tumors appeared to drive the differences. Conclusions We observed a trend toward improved outcomes in gBRCA1/2 PV carriers compared with noncarriers. These findings suggest that carriers should not receive more aggressive treatment solely based on their germline mutation status. Prospective clinical trials in this population are warranted.
Abstract TU118: Longitudinal Trajectories of Kidney Function in Heart Failure: A community study
Joo, Jungnam , Ganguli, Anirban , Bielinski, Suzette, Chamberlain, Alanna, Shearer, Joe, Roger, Veronique, Kim, Ji‐Eun , Bielinski, Suzette J. , Chamberlain, Alanna M. , Shearer, Joe, Roger, Véronique L.

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.tu118 Get It

Introduction: Chronic kidney disease affects nearly half of heart failure (HF) patients, underscoring the importance of regular kidney function monitoring. However, longitudinal trajectories of kidney function in HF are not well characterized. Identifying clinical factors linked to long-term changes is critical for improving monitoring and informing early clinical decisions. Hypothesis: We hypothesized that longitudinal kidney function and its associations with clinical variables in HF patients differ from that of demographically similar comparators from the same community. Methods: We analyzed patients with validated HF from a community-based cohort and comparators individually matched to age and sex selected from participants in the Mayo Clinic Biobank cohort. Individuals with end-stage kidney disease, dialysis or kidney transplantation prior to enrollment were excluded. Serum creatinine-based estimated glomerular filtration rate (eGFR) from outpatient and inpatient visits was assessed from enrollment for up to 10 years of follow-up. The median of eGFR for 90-day intervals was used to estimate the follow-up eGFR (Figure 1) . We modeled percentage change from baseline and fit linear mixed-effect models with time, HF status, and their interaction to test whether the eGFR trajectories differed between the two groups. In addition, we examined the association between eGFR trajectories and clinical variables. Results: We studied 1182 HF patients and 825 comparators with at least three eGFR measurements. Median follow-up was 5 years (IQR: 3-10) for HF patients and 8 years (6-9) for comparators. In total, 16245 serum creatinine measurements from HF patients and 9858 from comparators were analyzed. Median age at enrollment was 76 years (67-84) for HF patients and 78 years (70-83) for comparators. A greater decline in percentage change in eGFR was observed in HF patients (-4.23%, 95% CI: -4.75 to -3.70% per year) than in comparators (-1.90%, 95% CI: -2.51 to -1.29% per year; P<0.001, Figure 2 ). Among HF patients, the decline in percentage change in eGFR was greater in the presence of diabetes, hyperlipidemia, or a higher comorbidity burden. Conclusions: In this community study, HF patients exhibited a greater percentage decline in eGFR compared to community comparators. Among HF patients, eGFR decline was more strongly associated with comorbidities—particularly metabolic risk factors—highlighting the relevance of the cardiovascular-kidney-metabolic syndrome in HF.
Genetic and Pathological Characteristics of Frontotemporal Dementia with Right Anterior Temporal Predominance: A Multicenter Retrospective Cohort Study
Ulugut, Hülya , Spinelli, Edoardo G., Samancı, Bedia , Santillo, Alexander , Waldö, Maria Landqvist , Riedl, Lina , Stock, Jan Van den, Vandenbulcke, Mathieu, Vandenberghe, Rik, Laforce, Robert, Ducharme, Simon , Pressman, Peter , Tartaglia, Carmela M., Caramelli, Paulo, Souza, Leonardo Cruz de, Takada, Leonel Tadao, Morin, Alexandre , Schroeter, Matthias L, Kim, Eun‐Joo, Moon, So Young, Agosta, Federica, Filippi, Massimo, Gürvit, Hakan, Galimberti, Daniela, Miller, Bruce L., Sturm, Virginia E. , Miyagawa, Toji , Whitwell, Jennifer L., Boeve, Brad F, Rohrer, Jonathan D., Tempini, Maria Luisa Gorno , Josephs, Keith A., Warren, Jason D. , Rankin, Katherine, Group, International rtvFTD Working, Agosta, Federica , Spinelli, Edoardo Gioele , Agosta, Federica , Younes, Kyan , Bertoux, Maxime , Montembeault, Maxime , Fumagalli, Giorgio , Ghirelli, Alma , Jung, Na‐Yeon , Illán‐Gala, Ignacio , Thompson, J. C. , Kobylecki, Christopher , Englund, Elisabet , Stock, Jan Van den , Vandenbulcke, Mathieu , Vandenberghe, Rik , Laforce, Robert , Caramelli, Paulo , Souza, Leonardo Cruz de , Takada, Leonel Tadao , Schroeter, Matthias L , Kim, Eun‐Joo , Moon, So Young , Canu, Elisa , Filippi, Massimo , Gurvit, Hakan I. , Diehl‐Schmid, Janine , Galimberti, Daniela , Lebouvier, Thibaud , Miller, Bruce L. , Whitwell, Jennifer L. , Rohrer, Jonathan D. , Josephs, Keith A. , Snowden, Julie S. , Rankin, Katherine P. , Pijnenburg, Yolande A.L.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S3 | Pages: No page available

10.1002/alz70857_103987 Get It

Abstract Background Frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominant atrophy is an emerging area of interest. Recent findings by the International Working Group (IWG) have identified this subtype as having a distinct clinical profile within the FTD spectrum (Ulugut et al., 2024, A&D). However, its genetic and pathological underpinnings remain unexplored in large, multicultural cohorts. Methods Retrospective analyses encompassing clinical, genetic, pathological, and neuroimaging data from 23 IWG sites across 13 countries in Asia, Middle East, Europe, North and South America were conducted. The study included 444 patients with FTD exhibiting predominant RATL atrophy. Results Genetic screening was performed on 51% ( n = 225) of the cohort for at least the major frontotemporal lobar degeneration (FTLD) mutations including microtubule‐associated protein tau ( MAPT ), progranulin ( GRN ), and chromosome 9 open reading frame 72 ( C9orf72 ), or dementia panels encompassing extended sets of genes. Of these, 81% were sporadic, showing negative results for the screened genes and a modified Goldman Score of ≥ 3, indicating a negative family history for dementia. The MAPT mutation was the most common genetic variant, identified in 7% of the screened cases (Figure 1). Pathological confirmation was available for 63 patients. Among the sporadic cases, transactive response DNA‐binding protein 43 type C (TDP‐C) pathology was most prevalent (60%, n = 32), while tau‐MAPT pathology was most common in the genetic cases (38%, n = 16). Fifteen cases did not fit neatly into genetic or sporadic categories, displaying heterogeneous pathologies (Figure 2). At the initial visit, compared to genetic cases, patients with TDP‐C pathology were older, and more frequently exhibited semantic deficits, with less frequent attention difficulties and executive dysfunction. No differences were observed in sex distribution, symptom duration or disease severity between genetic and sporadic TDP‐C cases. However, left handedness was more common in TDP‐C cases (14%) compared to genetic cases (5%). Conclusion While FTD with RATL atrophy primarily appears sporadic, a significant proportion of cases exhibit genetic variants. These sporadic and genetic subtypes display distinct neuropathological features and clinical manifestations. Given the implications for therapeutic strategies, precise clinical and molecular subtyping is critical for enhancing patient management and ensuring appropriate enrollment in clinical trials.
External assessment of an artificial intelligence-enabled electrocardiogram for aortic stenosis detection
Kim, Darae , Kim, Jihoon, Kim, Eun Kyoung , Park, Sung Ji, Choi, Jin-Oh , Friedman, Paul A. , Oh, Jae K. , Lee, Eunjung , Kim, Jihoon, Kim, Eun Kyoung , Chang, Sung‐A , On, Young Keun , Attia, Zachi I. , Park, Kyoung‐Min

Mayo Clinic

European Heart Journal - Digital Health | July 1, 2025 | Volume: 6 | Issue: 4 | Pages: 656-664

10.1093/ehjdh/ztaf067 | PMID 40703138 Get It

Abstract Aims To assess the performance of an artificial intelligence-enabled electrocardiogram (AI-ECG) algorithm in identifying patients with moderate to severe aortic stenosis (AS) in an Asian cohort from a tertiary care centre. Methods and results We identified a randomly selected patients ≥60 years old who underwent echocardiography and ECG within in 31 days between 2012 and 2021 at the Samsung Medical Center in Korea. Patients with previous cardiac surgery, prosthetic valves, or pacemakers were excluded. The AI-ECG model, originally developed and validated by Mayo Clinic in the USA, was applied without fine-tuning. Performance metrics, including the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy, were calculated to compare AI-ECG predictions with TTE-confirmed AS status. Among 5425 patients, 1095 had moderate to severe AS, and 4330 age- and sex-matched patients without AS were included as controls. The AI-ECG model achieved an AUC of 0.85 (95% CI: 0.84–0.87) in detecting moderate to severe AS. Sensitivity, specificity, PPV, NPV, and accuracy were 0.83, 0.65, 0.37, 0.94, and 68.29%, respectively. The model's performance was consistent across various age and sex subgroups, with sensitivity increasing in older patients. Conclusion The AI-ECG model developed in the USA demonstrated comparable performance in detecting moderate to severe AS in an Asian cohort compared with its original validation population. These findings highlight the potential utility of AI-ECG as a non-invasive screening tool for AS across diverse patient populations.
Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via FOXA1 Inhibition
Song, Christine , Jung, Dawa, Kendi, A. Tuba , Rho, Jin Kyung , Kim, Eun-Joo , Horn, Ian, Curran, Geoffry L., Ghattamaneni, Sujala, Shim, Ji Yeon, Kang, Pil Soo, Dewan, Sannidhi, Lowe, Val J. , Lee, Seung Baek , Kendi, A Tuba , Kang, Daehun , Thakkar, Jay B, Lowe, Val J , Lee, Seung Baek , Horn, Ian, Curran, Geoffry L., Kang, Daehun , Thakkar, Jay B. , Dewan, Sannidhi

Mayo Clinic

International Journal of Molecular Sciences | July 8, 2024 | Volume: 25 | Issue: 13 | Pages: 7494

10.3390/ijms25137494 | PMID 39000600 Get It

Women with type 2 diabetes (T2D) have a higher risk of being diagnosed with breast cancer and have worse survival than non-diabetic women if they do develop breast cancer. However, more research is needed to elucidate the biological underpinnings of these relationships. Here, we found that forkhead box A1 (FOXA1), a forkhead family transcription factor, and metformin (1,1-dimethylbiguanide hydrochloride), a medication used to treat T2D, may impact hormone-receptor-positive (HR+) breast cancer (BC) tumor cell growth and metastasis. Indeed, fourteen diabetes-associated genes are highly expressed in only three HR+ breast cancer cell lines but not the other subtypes utilizing a 53,805 gene database obtained from NCBI GEO. Among the diabetes-related genes, FOXA1, MTA3, PAK4, FGFR3, and KIF22 were highly expressed in HR+ breast cancer from 4032 breast cancer patient tissue samples using the Breast Cancer Gene Expression Omnibus. Notably, elevated FOXA1 expression correlated with poorer overall survival in patients with estrogen-receptor-positive/progesterone-receptor-positive (ER+/PR+) breast cancer. Furthermore, experiments demonstrated that loss of the FOXA1 gene inhibited tumor proliferation and invasion in vitro using MCF-7 and T47D HR+ breast cancer cell lines. Metformin, an anti-diabetic medication, significantly suppressed tumor cell growth in MCF-7 cells. Additionally, either metformin treatment or FOXA1 gene deletion enhanced tamoxifen-induced tumor growth inhibition in HR+ breast cancer cell lines within an ex vivo three-dimensional (3D) organoid model. Therefore, the diabetes-related medicine metformin and FOXA1 gene inhibition might be a new treatment for patients with HR+ breast cancer when combined with tamoxifen, an endocrine therapy.
International consensus on the management of large (≥20 mm) colorectal laterally spreading tumors: World Endoscopy Organization Delphi study
Rex, Douglas K. , Aihara, Hiroyuki , Bastiaansen, Barbara A.J. , Bechara, Robert , Bhatt, Amit , Bourke, Michael J. , Byeon, Jeong‐Sik , Chino, Akiko , Goldblum, John R. , Ho, Shiaw Hooi , Jung, Yunho , Kawachi, Hiroshi , Khashab, Mouen A., Khomvilai, Supakij , Messmann, Helmut , Mori, Yuichi, Nakanishi, Yukihiro , Ngamruengphong, Saowanee , Parra‐Blanco, Adolfo , Pinto, Rafael Castilho , Pioche, Mathieu , Pohl, Heiko , Rastogi, Amit , Repici, Alessandro , Sethi, Amrita , Suzuki, Noriko, Tanaka, Shinji , Vieth, Michael, Yokoi, Chizu , Saito, Yutaka , Renteln, Daniel von , Chino, Akiko , Chiu, Philip Wai Yan , Elkholy, Shaimaa , Kawachi, Hiroshi , Yamamoto, Hironori , Yang, Dong-Hoon , Saito, Yutaka , Bhatt, Amit , Bechara, Robert , Djinbachian, Roupen , Chiu, Han‐Mo , Fukami, Norio , Bhandari, Pradeep , Cardoso, Daniela, Dekker, Evelien , Draganov, Peter V. , Emura, Fabian , Haji, Amyn , Khashab, Mouen A. , Kim, Eun Ran , Maselli, Roberta , Moons, Leon M.G. , Pellisé, Maria , Singh, Rajvinder

Mayo Clinic

Digestive Endoscopy | June 27, 2024 | Volume: 36 | Issue: 11 | Pages: 1253-1268

10.1111/den.14826 | PMID 38934243 Get It

ObjectivesThere have been significant advances in the management of large (≥20 mm) laterally spreading tumors (LSTs) or nonpedunculated colorectal polyps; however, there is a lack of clear consensus on the management of these lesions with significant geographic variability especially between Eastern and Western paradigms. We aimed to provide an international consensus to better guide management and attempt to homogenize practices.MethodsTwo experts in interventional endoscopy spearheaded an evidence‐based Delphi study on behalf of the World Endoscopy Organization Colorectal Cancer Screening Committee. A steering committee comprising six members devised 51 statements, and 43 experts from 18 countries on six continents participated in a three‐round voting process. The Grading of Recommendations, Assessment, Development and Evaluations tool was used to assess evidence quality and recommendation strength. Consensus was defined as ≥80% agreement (strongly agree or agree) on a 5‐point Likert scale.ResultsForty‐two statements reached consensus after three rounds of voting. Recommendations included: three statements on training and competency; 10 statements on preresection evaluation, including optical diagnosis, classification, and staging of LSTs; 14 statements on endoscopic resection indications and technique, including statements on en bloc and piecemeal resection decision‐making; seven statements on postresection evaluation; and eight statements on postresection care.ConclusionsAn international expert consensus based on the current available evidence has been developed to guide the evaluation, resection, and follow‐up of LSTs. This may provide guiding principles for the global management of these lesions and standardize current practices.
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Appleman, Leonard J. , Kim, Se Eun , Harris, Wayne , Pal, Sumanta K. , Pins, Michael R., Kolesar, Jill , Agarwal, Neeraj , Vaena, Daniel A. , Ryan, Christopher W. , Hashmi, Mehmood, Costello, Brian A. , Cella, David , DiPaola, Robert S. , Parikh, Rahul A , Vaena, Daniel A , Costello, Brian A , Cella, David , Dutcher, Janice P. , Haas, Naomi B , Wagner, Lynne , Agarwal, Archana M , Appleman, Leonard , Wagner, Lynne I. , Carducci, Michael A.

Mayo Clinic

Journal of Clinical Oncology | March 28, 2024 | Volume: 42 | Issue: 17 | Pages: 2061-2070

10.1200/jco.23.01544 | PMID 38531002 Get It

PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated analysis at 60.5-month median follow-up from random assignment (95% CI, 59.3 to 71.0) showed that the 3-year DFS was 27.4% (95% CI, 17.9 to 41.7) for pazopanib and 21.9% (95% CI, 13.3 to 36.2) for placebo. Hazard ratio (HR) for DFS was 0.90 ([95% CI, 0.60 to 1.34]; Pone-sided = .29) in favor of pazopanib. Three-year overall survival (OS) was 81.9% (95% CI, 72.7 to 92.2) for pazopanib and 91.4% (95% CI, 84.4 to 98.9) for placebo. The HR for OS was 2.55 (95% CI, 1.23 to 5.27) in favor of placebo ( Ptwo-sided = .012). Health-related quality-of-life measures deteriorated in the pazopanib group during the treatment period. CONCLUSION Pazopanib did not improve DFS as the primary end point compared with blinded placebo in patients with mRCC with NED after metastasectomy. In addition, there was a concerning trend favoring placebo in OS.
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) unde
Kim, Se Eun , Master, Viraj A. , Baniak, Nick , Tapia, Elsa Li Ning, Leibovich, Bradley C. , Shuch, Brian , Group, EA8143 Authors', Haas, Naomi B , McDermott, David F. , Signoretti, Sabina , Akgül, Mahmut , Palmer, Matthew R. , Emamekhoo, Hamid , Kapoor, Anil , Michaelson, M. Dror , Bratslavsky, Gennady , Carducci, Michael A. , Allaf, Mohamad E , Group, EA8143 Authors'

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 4541-4541

10.1200/jco.2023.41.16_suppl.4541 Get It

4541 Background: PROSPER is a phase 3 National Clinical Trials Network study that accrued pts with clinical stage ≥T2 or TanyN+ RCC of any histology planned for radical/ partial nephrectomy. Pts were randomized to perioperative nivo followed by primary tumor resection and 9 cycles of nivo postoperatively or standard surgery followed by observation. To address concerns that core kidney bx might 1) not provide accurate diagnosis and 2) delay surgery due to adverse events (AEs) or scheduling, the study was amended from requiring all patients to undergo core bx prior to treatment for confirmation of RCC, to only require bx in patients randomized to the nivo arm. Herein, we report the accuracy and safety of primary tumor core bxs in predicting final histology and nuclear grade by both site and central pathology review as well as time from enrollment to surgery. We also report AEs of preoperative nivo. Methods: Concordance of both core bx and primary tumor by site and central pathology review of histology and grade (1-2 vs 3-4) are reported, along with the Cohen’s Kappa value, which measures the agreement and concordance (kappa=0 is no concordance and 1 is highest). AEs relating to core bxs and preoperative nivo, as well as time from enrollment to surgery for each arm, comparing pre- and post-amendment (dropping bx requirement in surgery alone arm) are also reported. Results: 387/404 pts in the nivo arm and 171/415 pts in the surgery alone arm had core bxs. 632 patients had both central pathology and site review available. 41 of all randomized patients (819) were considered as non-RCC and 26/41 were identified via bx. The median times from enrollment to surgery for nivo and control arms pre-amendment were 32d vs 19 d, and post-amendment were 21 d vs 14 d, respectively. The median (25th-75th percentile) number of days from last preoperative nivo to surgery was 14 d (9-20). AEs related to core bx, generally from bleeding, were reported in 13/558 (2.3%) pts. 2/13 bxs resulted in life-threatening complications. 21/353 (6%) of pts receiving nivo pre-surgery had ≥ grade 3-5 AE attributed to nivo. 181/353 (51%) pts had any grade AE attributed to nivo. Concordance between bxs and primary tumor pathologies for determining histological subtype was Kappa = 0.62. Agreement between central pathology and originating site review of primary tumor for determining nuclear grade was Kappa = 0.56, and concordance of histology was Kappa = 0.78. Conclusions: The PROSPER trial use of core bxs in advance of neoadjuvant therapy was generally safe, largely consistent with primary tumor histology and grade, and did not delay resection of the primary tumor. AEs of preoperative nivo were consistent with nivo AEs in metastatic disease. This approach is valid for future neoadjuvant trials. Clinical trial information: NCT03055013 .
Clonally Selected Lines After CRISPR-Cas Editing Are Not Isogenic
Panda, Arijit , Mariani, Jessica , Jang, Yeongjun , Kollmeyer, Thomas M. , Sarkar, Gobinda , Kim, Ji‐Eun , Yoon, Wan Hee , Jenkins, Robert B. , Vaccarino, Flora M. , Abyzov, Alexej , Kollmeyer, Thomas , Vaccarino, Flora M , Abyzov, Alexej , Jang, Yeongjun , Šuvakov, Milovan , Drucker, Kristen , Park, Yohan , Bae, Taejeong

Mayo Clinic

The CRISPR Journal | April 18, 2023 | Volume: 6 | Issue: 2 | Pages: 176-182

10.1089/crispr.2022.0050 | PMID 37071670 Get It

The CRISPR-Cas9 system has enabled researchers to precisely modify/edit the sequence of a genome. A typical editing experiment consists of two steps: (1) editing cultured cells; (2) cell cloning and selection of clones with and without intended edit, presumed to be isogenic. The application of CRISPR-Cas9 system may result in off-target edits, whereas cloning will reveal culture-acquired mutations. We analyzed the extent of the former and the latter by whole genome sequencing in three experiments involving separate genomic loci and conducted by three independent laboratories. In all experiments we hardly found any off-target edits, whereas detecting hundreds to thousands of single nucleotide mutations unique to each clone after relatively short culture of 10–20 passages. Notably, clones also differed in copy number alterations (CNAs) that were several kb to several mb in size and represented the largest source of genomic divergence among clones. We suggest that screening of clones for mutations and CNAs acquired in culture is a necessary step to allow correct interpretation of DNA editing experiments. Furthermore, since culture associated mutations are inevitable, we propose that experiments involving derivation of clonal lines should compare a mix of multiple unedited lines and a mix of multiple edited lines.